Drug intelligence / Profile preview

ALYGLO

Development stage: Approved
Lead developer: GC Biopharma
Administration: Intravenous

Overview

ALYGLO is a 10% immune globulin liquid for intravenous injection, used to treat primary humoral immunodeficiency (PI) in adults. It supplies a broad spectrum of neutralizing IgG antibodies to bacterial and viral pathogens, helping restore abnormally low IgG levels. Developed by GC Biopharma Corp., ALYGLO is derived from donated human plasma and undergoes rigorous purification to ensure safety.

Brand names: ALYGLO
Other names: Immune Globulin Intravenous, Human-stwk

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on ALYGLO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALYGLO.

Explore the full profile